AEON Biopharma regains NYSE American listing compliance on stockholders’ equity
AEON•NYSE American compliance restored
AEON Biopharma received notice from NYSE American confirming that it has regained compliance with the exchange’s continued listing standards tied to stockholders’ equity.
NYSE American cited resolution of deficiencies under Sections 1003(a)(i) and 1003(a)(ii), and the “.BC” trading indicator is expected to be removed.
Compliance followed July 2026 offering
The company said compliance followed a July 2026 underwritten offering that generated about $13.6 million in net proceeds, lifting stockholders’ equity above the $4 million minimum.
